Lake Street analyst Brooks O’Neil raised the firm’s price target on Harrow to $55 from $45 and keeps a Buy rating on the shares after Harrow announced the relaunch of TRIESENCE, a preservative-free corticosteroid for visualization during vitrectomy and treatment of inflammatory eye conditions that do not respond to standard therapies. 2024 revenue guidance does not account for any TRIESENCE revenue and the firm has $0 in its model for the drug, noting that management maintained previous revenue guidance of more than $180M on the last earnings call, and adding that it thinks “there will be upside to this number.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow announces relaunch of TRIESENCE for vitrectomy visualization, inflamation
- Harrow announces expansion of corporate headquarters in Nashville
- Harrow Health Unveils Performance Strategy to Investors
- Harrow price target raised to $45 from $30 at Craig-Hallum
- Harrow price target raised to $50 from $29 at B. Riley